Guggenheim Reiterates Buy Rating on Regeneron Pharmaceuticals, Inc. (REGN)
Rating Change Guggenheim analysts reiterated a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on August 03, 2026. Market Context Regeneron Pharmaceuticals, Inc.
Read more
